Nucleix Ltd.
- Country
- 🇮🇱Israel
- Ownership
- Holding
- Established
- 2008-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.nucleix.com
Clinical Trials
9
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Bladder EpiCheck European Haematuria Study
- Conditions
- Urothelial Carcinoma of the Urinary BladderHematuriaUrothelial Carcinoma of the Renal Pelvis and UreterCystoscopyUrothelial Carcinoma Bladder
- First Posted Date
- 2025-02-10
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Nucleix Ltd.
- Target Recruit Count
- 600
- Registration Number
- NCT06818136
- Locations
- 🇬🇧
NHS Lothian, Edinburgh, United Kingdom
Lung EpiCheck Biomarkers Development Study
- Conditions
- Lung Cancer
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Nucleix Ltd.
- Target Recruit Count
- 6000
- Registration Number
- NCT06245876
- Locations
- 🇺🇸
Life Spring Clinical Research, Miami, Florida, United States
🇺🇸Emerald Coast OBGYN, Panama City, Florida, United States
🇺🇸Ochsner LSU Health Shreveport - Regional Urology, Shreveport, Louisiana, United States
Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior History or Evidence of Bladder Cancer
- Conditions
- Non-Muscle Invasive Bladder Urothelial CarcinomaNon Muscle Invasive Bladder Cancer
- First Posted Date
- 2023-09-01
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Nucleix Ltd.
- Target Recruit Count
- 168
- Registration Number
- NCT06020807
- Locations
- 🇺🇸
Urology San Antonio, San Antonio, Texas, United States
Determination and Validation of a Multi-analyte Assay for Lung Cancer Screening
- Conditions
- Lung Cancer
- First Posted Date
- 2021-07-20
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- Nucleix Ltd.
- Target Recruit Count
- 5000
- Registration Number
- NCT04968548
- Locations
- 🇺🇸
Scripps Memorial Hospital, Encinitas, California, United States
🇺🇸Centura Health, Lakewood, Colorado, United States
🇺🇸VA Connecticut Healthcare System, West Haven, Connecticut, United States
Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA
- Conditions
- CancerHematologic NeoplasmsSolid Tumor
- First Posted Date
- 2020-02-11
- Last Posted Date
- 2022-06-08
- Lead Sponsor
- Nucleix Ltd.
- Target Recruit Count
- 800
- Registration Number
- NCT04264767
- Locations
- 🇺🇸
Los Angeles Hematology Oncology Medical Group - Wilson Terrace, Glendale, California, United States
🇺🇸Los Angeles Hematology Oncology Medical Group - Good Samaritan Medical Offices, Los Angeles, California, United States
🇮🇱Sourasky Medical Center, Tel Aviv, Israel
- Prev
- 1
- 2
- Next